Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Hematology/Oncology
Credits Available: 5.0 AMA PRA Category 1 Credit

Multiple myeloma (MM) is a clonal plasma cell disorder arising from the bone marrow and is the second most common hematologic malignancy in the United States (US), with an incidence of approximately 35,000 new cases per year. While progression-free survival (PFS) benefit is often seen with MM therapeutics, overall survival (OS) benefit is rarely seen with novel therapies, and improvements in PFS are still associated with adverse events and long-term disease refractoriness. Over the past few decades, rigorous pre-clinical and clinical research has led to the discovery of novel therapies that have dramatically changed the treatment landscape of MM in the frontline as well as in the relapsed/refractory setting. Despite implementing multimodal approaches to treat MM, the major challenge remains that the vast majority of patients eventually relapse and become refractory to multiple drug classes. Additionally, patients require continuous treatment throughout the disease course, which can negatively affect their quality of life due to potential therapy-related side effects. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with multiple myeloma.


CME/CE Accreditation Information

Itinerary

Part One - Baseline Assessment, Self Study, Live Group Discussion 1, Final Assessment

New Frontiers with BCMA Targeting in the Treatment of Heavily Relapsed Multiple Myeloma - Baseline Assessment

The following questions are designed to assess your knowledge and practice of patients with relapsed refractory multiple myeloma.

Module 1: BCMA Targeting - Mechanisms of Action in RRMM

This module will cover the mechanism of action and the role of BCMA in multiple myeloma (MM).

Module 2: Clinical Trial Data for Current and Emerging BCMA-Targeting Agents

This module will cover recently approved and emerging bispecific antibodies and approved CAR T-cell therapies.

Module 3: Minimal Residual Disease (MRD) Assessment in MM

This module will cover minimal residual disease (MRD) assessment in MM.

Module 4: BCMA-Targeting Therapy: Management Specifics

This module will cover specific issues to consider when using BCMA-targeting agents.

New Frontiers with BCMA Targeting in the Treatment of Heavily Relapsed Multiple Myeloma - Final Assessment

The following questions are designed to assess your knowledge and practice of patients with relapsed refractory multiple myeloma.

Live Group Discussion 1

During this session, we will review the self-study modules and discuss approaches to treatment that offer optimal care to patients with relapsed refractory multiple myeloma.

Part Two - Group Challenge, Action Plan, Live Group Discussion 2

Multiple Myeloma Group Challenge: Jeffery's Case

Meet Jeffery, a 59-year-old man with a history of IgG kappa multiple myeloma.

Your Action Plan In Heavily Relapsed Multiple Myeloma

In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with relapsed refractory multiple myeloma.

Live Group Discussion 2

During this session, we will review the patient case and discuss treatment plans. Additionally, we will share our action plans and how this CME activity will shape our practice regarding patient care.

Interested in becoming a Group Leader?

Requirements:
Experts in the management of patients with multiple myeloma, including physicians and advanced practice providers. Apply Now

Interested in participating in this curriculum? You can join one of the following groups:

BD
Binod Dhakal, MD, MS
Associate Professor of Medicine
SA
Syed Abbas Ali, MD
Dickran Kazandjian, MD
Professor of Medicine
ON
OMAR NADEEM, MD
SR
Shambavi Richard, MD, MD
Associate Professor of Medicine
MK
Mehmet Kocoglu, MD
Associate Professor